You are viewing the site in preview mode

Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Fig. 1

Kaplan Meier curve estimating PFS for 55 patients from the next line of systemic therapy for kidney cancer after discontinuation of IO-VEGF. Median PFS was 12 months (95% CI, 8.2–24.5) and 12-month PFS probability was 49.6% (95% CI, 33.2–64.0). Median follow up time for progression-free survivors was 8.5 months (range: 0, 30). PFS (Progression Free Survival), IO-VEGF (Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us